Showing results (1-10 of 18) with videos related to

Sort By:
Pageof 2
Journal of Nuclear Medicine : Official Publication, Society of Nuclear Medicine|April 21, 1999
Comparative 99mTc-sestamibi and 3H-daunomycin uptake in human carcinoma cells: relation to the MDR phenotype and effects of reversing agentsA Cayre, N Moins, F Finat-Duclos, et al.
Journal of Nuclear Medicine : Official Publication, Society of Nuclear Medicine|November 28, 1997
Comparison between technetium-99m-sestamibi and hydrogen-3-daunomycin myocardial cellular retention in vitroA Cayre, N Moins, F Finat-Duclos, et al.
Critical Reviews in Oncology/Hematology|March 26, 2013
Tu-be or not tu-be: that is the question… about serous ovarian carcinogenesisG Chene, J Dauplat, N Radosevic-Robin, et al.
Anti-Cancer Drugs|November 1, 1996
In vitro detection of the MDR phenotype in rat myocardium: use of PCR, [3H]daunomycin and MDR reversing agentsA Cayre, N Moins, F Finat-Duclos, et al.
Anticancer Research|August 23, 2000
Effects of MDR reversing agent combinations on the 3H-daunomycin accumulation in drug-sensitive and drug-resistant human cancer cellsN Moins, A Cayre, S Chevillard, et al.
Journal De Gynecologie, Obstetrique Et Biologie De La Reproduction|November 28, 2012
[Early detection of ovarian cancer: tomorrow? A review]G Chene, F Penault-Llorca, N Robin, et al.
Gynecologie, Obstetrique & Fertilite|October 25, 2011
[Don't forget fallopian tubes! A morphologic and immunohistochemical study about Fallopian tubes with genetic risk (BRCA mutation)]G Chêne, I Raoelfils, A Cayre, et al.
European Journal of Histochemistry : EJH|July 8, 2014
Morphological and immunohistochemical study of ovarian and tubal dysplasia associated with tamoxifenG Chene, N Radosevic-Robin, A S Tardieu, et al.
Pigment Cell & Melanoma Research|May 7, 2010
Anti-melanoma efficacy of internal radionuclide therapy in relation to melanin target distributionM Bonnet, F Mishellany, J Papon, et al.
ESMO Gastrointestinal Oncology|February 6, 2026
High prevalence of NTRK fusions in sporadic dMMR/MSI mCRC RAS/RAF wild-type: an opportunity for a post-immune checkpoint inhibitors progression rescue strategyM Svrcek, A Cayre, T Samaille, et al.
Pageof 2